{"schema_version":"secwatch.filing_event.v1","accession":"0001285550-24-000120","form_type":"8-K","ticker":"CLPT","cik":"0001285550","company_name":"ClearPoint Neuro, Inc.","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.970909+00:00","generated_at":"2026-05-30T03:20:14.981938+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ClearPoint Neuro Q3 revenue $8.1M (+41% YoY); FY guidance reaffirmed","bullets":["Record quarterly revenue of $8.1M, up 41% YoY; navigation & device revenue $2.9M (+49%).","Biologics & drug delivery revenue $4.4M (+27%); capital equipment revenue $0.8M (+133%).","Gross margin 60% vs 57% YoY; operating expenses $10M (up from $8.2M) on higher personnel and development costs.","Cash $21.6M; fully repaid $10M convertible note leaving no debt; operational cash burn cut 33% to $1.2M.","Activated 5 new centers in Q3 (19 YTD, ~3x historic rate); FY 2024 revenue outlook held at $30-33M."],"urls":{"canonical":"https://secwatch.observer/filing/0001285550-24-000120","json":"https://secwatch.observer/filing/0001285550-24-000120.json","markdown":"https://secwatch.observer/filing/0001285550-24-000120.md","text":"https://secwatch.observer/filing/0001285550-24-000120.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1285550/000128555024000120/0001285550-24-000120-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1285550/000128555024000120/clpt-20241107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:20:14.981938+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}